The Role of Body Mass Index in Determining the Efficacy of Nivolumab for Patients with Advanced Non-Small Cell Lung Cancer
{{output}}
BACKGROUND Non-small cell lung cancer (NSCLC) comprises 85% of lung cancers with poor prognosis. Immune checkpoint inhibitors (ICIs), particularly nivolumab, show survival benefits in advanced NSCLC. The effect of body mass index (BMI) on immunotherapy outcome... ...
